Takeda Japan candesartan promotion, study under scrutiny
This article was originally published in Scrip
Executive Summary
Takeda has been forced to defend a major Japanese postmarketing study with its blockbuster antihypertensive Blopress (candesartan) after media in Japan highlighted issues related to potential conflict of interest and the presentation and use of results in promotional materials.